CAM
PCRX icon

Castlerock Asset Management’s Pacira BioSciences PCRX Stock Holding History

Castlerock Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-31,268
Closed -$2.87M – 31
2014
Q2 		$2.87M Buy
31,268
+19,547
+167% +$1.49M 8.38% 1
2014
Q1 		$820K Buy
+11,721
New +$797K 2.38% 22

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Castlerock Asset Management's PCRX Position: Q3 2014 in Review

Castlerock Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2014, closing a stake of 31,268 shares — an estimated $2.87M sold.

Castlerock Asset Management first reported a position in PCRX in Q1 2014 and held it in 2 quarters. The position peaked at $2.87M in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

  • Castlerock Asset Management reported no remaining Pacira BioSciences position as of Q3 2014 after selling out during the quarter.
  • Castlerock Asset Management sold 31,268 Pacira BioSciences shares in Q3 2014, an estimated $2.87M.
  • Castlerock Asset Management first reported a position in Pacira BioSciences in Q1 2014 and held it in 2 quarters.
  • Castlerock Asset Management's Pacira BioSciences position peaked at $2.87M in Q2 2014.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on Castlerock Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.